Andrx is in discussions with FDA to market Altocor (lovastatin extended-release) under a new name "to avoid possible confusion in the marketplace." Company says name change is unrelated to Kos' lawsuit alleging a likelihood of confusion with its cholesterol-lowering agent Advicor (niacin/lovastatin). FDA already has approved Altoprev as an alternative brand for Altocor (1"The Pink Sheet" Sept. 15, 2003, In Brief)...

The final opinion of ECHA’s Socio-Economic Analysis Committee, published on 1 March, is largely unchanged from its July 2020 draft opinion with regard to microplastic in cosmetic products. That means industry may have to convince EU member state authorities that the restriction proposal has a serious proportionality problem.

Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.